Article Text

This article has a correction. Please see:

other Versions

PDF
Prucalopride (resolor®) in the treatment of severe chronic constipation in patients dissatisfied with laxatives
  1. Jan Tack (jan.tack{at}med.kuleuven.be)
  1. University of Leuven, Belgium
    1. Marc Van Outryve (marc.van.outryve{at}skynet.be)
    1. University of Antwerp, Belgium
      1. G Beyens (geert.beyens{at}movetis.com)
      1. Movetis NV, Turnhout, Belgium
        1. René Kerstens (rene.kerstens{at}movetis.com)
        1. Movetis NV, Turnhout, Belgium
          1. Godelieve Vandeplassche (lieve.vandeplassche{at}movetis.com)
          1. Movetis NV, Turnhout, Belgium

            Abstract

            Objective: We aimed to determine the efficacy, impact on quality of life (QOL), and safety of prucalopride, a selective, high-affinity 5-HT4 receptor agonist, in patients with chronic constipation (CC).

            Methods: In this multi-centre, randomized, placebo-controlled, parallel-group, phase III study, patients with CC (≤2 spontaneous complete bowel movements ([SCBM]/week) received 2 or 4 mg prucalopride or placebo, once daily, for 12 weeks. The primary efficacy endpoint was the proportion of patients reaching ≥3 SCBM/week. The key secondary efficacy endpoint was the proportion of patients having an increase of ≥1 SCBM/week. The primary QOL endpoint was the Patient Assessment of Constipation (PAC)-QOL satisfaction subscale score. Safety parameters included adverse events, laboratory values, and cardiovascular events.

            Results: Efficacy was evaluated over 713 patients. Averaged over 12 weeks, higher proportions of patients on prucalopride 2 mg (19.5%; p<0.01), 4 mg (23.6%; p<0.001) had ≥3 SCBM/week (or normalization of bowel function) compared with placebo (9.6%). Similar results were seen in the subgroup (83%) of patients dissatisfied with previous laxative treatment. Both doses of prucalopride also significantly improved secondary efficacy and QOL endpoints, including the proportion of patients with an increase of ≥1 SCBM/week, evacuation completeness, perceived disease severity and treatment effectiveness, and QOL. Prucalopride 4 mg significantly reduced the need for straining versus placebo (p<0.05). The most frequent treatment-related adverse events were headache and diarrhoea. Both doses of prucalopride were safe and well-tolerated.

            Conclusion: Prucalopride significantly and consistently improved bowel function, associated symptoms and satisfaction in chronically constipated patients.

            Statistics from Altmetric.com

            Request permissions

            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

            Linked Articles

            • Digest
              Robin Spiller Magnus Simren
            • Miscellanea
              BMJ Publishing Group Ltd and British Society of Gastroenterology